OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
SPECI60

Inspecs Group PLC

Medical Equipment, Supplies & DistributionVerified

Inspecs Group PLC has a debt-to-equity ratio of 0.63, indicating a moderate reliance on debt financing, while its current ratio of 1.42 suggests adequate short-term liquidity to cover its obligations. However, the company's net cash position is negative after subtracting total debt, signaling potential liquidity constraints. Profitability metrics reveal a challenging operating environment for Inspecs Group PLC. The company reported a net loss of £4.6 million and an operating income of £2.75 million, translating to a return on equity of -4.67% and a return on assets of -2.09%. These figures fall below the typical performance benchmarks for the medical equipment and supplies industry, which generally expects positive returns on equity and assets. The company's revenue is distributed across two primary segments: Frames and Optics, which focuses on product distribution, and Manufacturing, which handles OEM and manufacturing distribution. Geographically, Inspecs Group PLC operates in the UK, Europe, the US, and China, with manufacturing facilities in Vietnam, China, the UK, and Italy. Its distribution network spans over 80 countries, reaching approximately 75,000 points of sale, indicating a broad but potentially fragmented market exposure. Looking ahead, Inspecs Group PLC is expected to face a mixed growth trajectory. While the company generated £198.26 million in revenue, its operating cash flow of £7.2 million and free cash flow of £5.29 million suggest some capacity to fund operations and reinvestment. However, the capital expenditure of £2.92 million indicates ongoing investment in infrastructure, which may pressure near-term profitability. Analysts have assigned a mean price target of £60.00, with a "hold" recommendation, reflecting cautious expectations. Risk factors for Inspecs Group PLC include liquidity constraints, as highlighted by the negative net cash position after debt. The company's dilution risk is currently assessed as low, with no significant changes in shares outstanding between basic and diluted figures. However, the net loss and negative returns on equity and assets suggest operational inefficiencies that could necessitate future capital raising, potentially increasing dilution risk. Recent events include the publication of the latest financial snapshot, which reveals the company's current financial position and performance. No recent filings or transcripts have been disclosed that would indicate significant strategic shifts or operational changes. The company's ongoing operations and capital expenditures suggest a focus on maintaining and expanding its manufacturing and distribution capabilities.

30-day price · SPECI+0.35 (+0.4%)
Low$82.00High$85.00Close$83.35As of12 May, 00:00 UTC
Profile
CompanyInspecs Group PLC
TickerSPECI.L
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryMedical Equipment, Supplies & Distribution
AI analysis

Business. Inspecs Group PLC designs, manufactures, and distributes eyewear solutions, including optical frames, lenses, and low vision aids, for global optical and non-optical retailers, independent opticians, and distributors, operating under both proprietary and private-label brands.

Classification. Inspecs Group PLC is classified under the industry "Medical Equipment, Supplies & Distribution" within the Healthcare Services & Equipment business sector, with a confidence level of 0.92.

Inspecs Group PLC has a debt-to-equity ratio of 0.63, indicating a moderate reliance on debt financing, while its current ratio of 1.42 suggests adequate short-term liquidity to cover its obligations. However, the company's net cash position is negative after subtracting total debt, signaling potential liquidity constraints. Profitability metrics reveal a challenging operating environment for Inspecs Group PLC. The company reported a net loss of £4.6 million and an operating income of £2.75 million, translating to a return on equity of -4.67% and a return on assets of -2.09%. These figures fall below the typical performance benchmarks for the medical equipment and supplies industry, which generally expects positive returns on equity and assets. The company's revenue is distributed across two primary segments: Frames and Optics, which focuses on product distribution, and Manufacturing, which handles OEM and manufacturing distribution. Geographically, Inspecs Group PLC operates in the UK, Europe, the US, and China, with manufacturing facilities in Vietnam, China, the UK, and Italy. Its distribution network spans over 80 countries, reaching approximately 75,000 points of sale, indicating a broad but potentially fragmented market exposure. Looking ahead, Inspecs Group PLC is expected to face a mixed growth trajectory. While the company generated £198.26 million in revenue, its operating cash flow of £7.2 million and free cash flow of £5.29 million suggest some capacity to fund operations and reinvestment. However, the capital expenditure of £2.92 million indicates ongoing investment in infrastructure, which may pressure near-term profitability. Analysts have assigned a mean price target of £60.00, with a "hold" recommendation, reflecting cautious expectations. Risk factors for Inspecs Group PLC include liquidity constraints, as highlighted by the negative net cash position after debt. The company's dilution risk is currently assessed as low, with no significant changes in shares outstanding between basic and diluted figures. However, the net loss and negative returns on equity and assets suggest operational inefficiencies that could necessitate future capital raising, potentially increasing dilution risk. Recent events include the publication of the latest financial snapshot, which reveals the company's current financial position and performance. No recent filings or transcripts have been disclosed that would indicate significant strategic shifts or operational changes. The company's ongoing operations and capital expenditures suggest a focus on maintaining and expanding its manufacturing and distribution capabilities.
Key takeaways
  • Inspecs Group PLC operates in the medical equipment and supplies industry with a global distribution network but faces profitability challenges.
  • The company's debt-to-equity ratio and negative net cash position highlight liquidity concerns.
  • Analysts have assigned a "hold" recommendation with a mean price target of £60.00, indicating cautious expectations.
  • The company's capital expenditures suggest ongoing investment in infrastructure, which may impact near-term profitability.
  • The company's operational inefficiencies, as reflected in negative returns on equity and assets, may necessitate future capital raising.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyGBP
Revenue$198.3M
Gross profit$103.5M
Operating income$2.8M
Net income-$4.6M
R&D
SG&A
D&A
SBC
Operating cash flow$7.2M
CapEx-$2.9M
Free cash flow$5.3M
Total assets$220.2M
Total liabilities$121.6M
Total equity$98.7M
Cash & equivalents
Long-term debt$62.5M
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0
FY-1
FY-2
FY-3
FY-4
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0
FY-1
FY-2
FY-3
FY-4
PeriodOCFCapExFCFSBC
FY0
FY-1
FY-2
FY-3
FY-4
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodOCFCapExFCFSBC
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$98.7M
Net cash-$62.5M
Current ratio1.4
Debt/Equity0.6
ROA-2.1%
ROE-4.7%
Cash conversion-1.6%
CapEx/Revenue-1.5%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Healthcare Services & Equipment · cohort 5 companies
MetricSPECIActivity
Op margin1.4%13.3% medp25 5.9% · p75 13.5%bottom quartile
Net margin-2.3%8.6% medp25 2.7% · p75 12.7%bottom quartile
Gross margin52.2%64.0% medp25 60.1% · p75 65.6%bottom quartile
R&D / revenue6.9% medp25 6.7% · p75 7.1%
CapEx / revenue-1.5%3.0% medp25 2.7% · p75 4.5%bottom quartile
Debt / equity63.0%69.3% medp25 63.4% · p75 74.5%bottom quartile
Observations
IR observations
Mean price target60.00 GBP
Median price target60.00 GBP
High price target60.00 GBP
Low price target60.00 GBP
Mean recommendation2.00 (1=strong buy, 5=strong sell)
Strong-buy count0.00
Buy count1.00
Hold count0.00
Sell count0.00
Strong-sell count0.00
Mean EPS estimate0.08 GBP
Last actual EPS0.04 GBP
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-10 12:01 UTC#768e4f20
Source: analysis-pipeline (hybrid)Generated: 2026-05-10 12:04 UTCJob: 2ba7bdcf